{"id":284,"date":"2026-04-11T10:47:45","date_gmt":"2026-04-11T10:47:45","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=284"},"modified":"2026-08-30T03:53:23","modified_gmt":"2026-08-30T03:53:23","slug":"lucigil-gilteritinib-40-mgx90-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/pt\/product\/lucigil-gilteritinib-40-mgx90-tablets\/","title":{"rendered":"LuciGil"},"content":{"rendered":"<p style=\"line-height:20px\"><span style=\";color:#3f3f3f;font-size:18px\"><strong style=\"\">HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"color:#3f3f3f;font-size:18px\"><strong style=\"\">These highlights do not include all the information needed to use LUCIGIL safely and effectively. See full prescribing information for LUCIGIL.<\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>INDICATIONS AND USAGE<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">LUCIGIL is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DOSAGE AND ADMINISTRATION<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">120 mg orally once daily.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DOSAGE FORMS AND STRENGTHS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Tablets: 40&nbsp;mg\u00d790 tablets<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>CONTRAINDICATIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Hypersensitivity to gilteritinib or any of the excipients. Anaphylactic reactions have been observed in clinical trials. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>WARNINGS AND PRECAUTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Posterior reversible encephalopathy syndrome (PRES): Discontinue LUCIGIL in patients who develop PRES. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Prolonged QT Interval: Interrupt and reduce LUCIGIL dosage in patients who have a QTcF &gt;500 msec. Correct hypokalemia or hypomagnesemia prior to and during LUCIGIL administration. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Pancreatitis: Interrupt and reduce the dose in patients who develop pancreatitis.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Embryo-Fetal Toxicity: LUCIGIL can cause fetal harm when administered to a pregnant woman. Advise of the potential risk to a fetus and to use effective contraception. <\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>ADVERSE REACTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">The most common adverse reactions (\u226520%) were transaminase increased, myalgia\/arthralgia, fatigue\/malaise, fever, mucositis, edema, rash, noninfectious diarrhea, dyspnea, nausea, cough, constipation, eye disorders, headache, dizziness, hypotension, vomiting, and renal impairment.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>DRUG INTERACTIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Combined P-gp and Strong CYP3A Inducers: Avoid concomitant use. <\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">\u2022&nbsp;Strong CYP3A Inhibitors: Consider alternative therapies. If the concomitant use of strong CYP3A inhibitors cannot be avoided, monitor patients more frequently for LUCIGIL adverse reactions.<\/span><\/p>\n<p style=\"margin-top:2px;margin-right:27px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>USE IN SPECIFIC POPULATIONS <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Lactation: Advise women not to breastfeed.<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">&nbsp;<\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\"><strong>Storage <\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height:20px\"><span style=\"font-size:16px;color:#3f3f3f\">Store at 20\u2103&nbsp;to 25\u2103&nbsp;(68\u2109&nbsp;to 77\u2109), excursions permitted between 15\u2103&nbsp;and 30\u2103&nbsp;(59\u2109&nbsp;and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture.&nbsp;<\/span><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LUCIGIL is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.<\/p>","protected":false},"featured_media":2148,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[21],"product_tag":[],"class_list":["post-284","product","type-product","status-publish","has-post-thumbnail","product_cat-blood-disease","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product\/284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/comments?post=284"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media\/2148"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media?parent=284"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_brand?post=284"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_cat?post=284"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_tag?post=284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}